Clinical Trials Directory

Trials / Completed

CompletedNCT06027021

Assessment of Hypoxia Before Radioembolization Treatment With 18F-FMISO PET

Status
Completed
Phase
Study type
Observational
Enrollment
64 (actual)
Sponsor
Ankara University · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers

Summary

Hypoxia is a known factor for resistance to radiotherapy in tumors. Response to transarterial radioembolization is known to be variable between different patients even if the same dose of radiation was delivered. In this study the investigators aim to quantify the hypoxia in the primary and secondary tumors of liver with 18F-FMISO PET before radioembolization and to prove any effect of the hypoxia, if present, on the dose that should be delivered to tumor to ensure treatment response.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TEST18F-Fluoromisonidazole PETImaging of hypoxia before radioembolization with 18F-Fluoromisonidazole PET.

Timeline

Start date
2023-08-15
Primary completion
2024-05-15
Completion
2024-07-15
First posted
2023-09-07
Last updated
2024-07-30

Locations

1 site across 1 country: Turkey (Türkiye)

Source: ClinicalTrials.gov record NCT06027021. Inclusion in this directory is not an endorsement.

Assessment of Hypoxia Before Radioembolization Treatment With 18F-FMISO PET (NCT06027021) · Clinical Trials Directory